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Protein interactionNeuronal ceroid lipofuscinoses (NCLs) are a genetically heterogeneous group of neurodegenerative diseases char-
acterized by cognitive and motor decline, epilepsy, visual loss and by lysosomal autoﬂuorescent inclusions. Two
distinct clinical phenotypes, the progressive epilepsy with mental retardation (EPMR) and a late-infantile variant
ofNCLs (CLN8-vLINCL) are associatedwithmutations in the CLN8 gene that encodes a transmembraneprotein pre-
dominantly located to the endoplasmic reticulum (ER). To gain insight into the function of CLN8 protein, we
employed the split-ubiquitin membrane-based yeast two-hybrid (MYTH) system, which detects protein-protein
interactions in a membrane environment, using the full-length human CLN8 as bait and a human brain cDNA
library as prey. We identiﬁed several potential protein partners of CLN8 and especially referred to VAPA,
c14orf1/hERG28, STX8, GATE16, BNIP3 and BNIP3L proteins that are associatedwith biologically relevant process-
es such as synthesis and transport of lipids, vesicular/membrane trafﬁcking, autophagy/mitophagy and apoptosis.
Interactions of CLN8 with VAPA and GATE16 were further validated by co-immunoprecipitation and co-
localization assays in mammalian cells. Using a new C-terminal-oriented CLN8 antibody, CLN8-VAPA interaction
was also conﬁrmed by co-staining in close spatial proximity within different CNS tissues. The results of this
study shed light on potential interactome networks of CLN8 and provide a powerful starting point for understand-
ing protein function(s) and molecular aspects of diseases associated with CLN8 deﬁciency.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
The neuronal ceroid lipofuscinoses (NCLs) are a group of autosomal
recessively inherited neurodegenerative disorders manifest mainly in
childhood [1,2]. More rare adult forms are also described and can present
with either dominant or recessive patterns of inheritance [1,3,4]. NCLs be-
long to the family of lysosomal storage diseases (LSDs), and are character-
ized by an intralysosomal accumulation of autoﬂuorescent lipopigment
and clinical symptoms such as progressive mental and motor deteriora-
tion, epilepsy, ataxia and visual loss. They vary in age of onset and severity
of disease progression, and are genetically linked to distinct genes – CLN1/
PPT1 (MIM 256730), CLN2/TPP1 (MIM 204500), CLN3 (MIM 204200),
CLN4/DNAJC5 (MIM 611203), CLN5 (MIM 256731), CLN6 (MIM 601780),
CLN7/MFSD8 (MIM 610951), CLN8 (MIM 600143), CLN10/CTSD (MIM
610127) – and differentmutations. Recently,more genes have been iden-
tiﬁed: CLN11/GRN (MIM138945), CLN12/ATP13A2 (MIM610513), CLN13/
CTSF (MIM 603539; http://www.ucl.ac.uk/ncl), and CLN14/KCTD7 (MIM
611725) [5–7]. CLN genes encode primarily soluble lysosomal proteinscine and Molecular Immunol-
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reticulum, although their distribution in other compartments is also doc-
umented [2,8]. The exact functions of many CLN proteins remain to be
deﬁned and the pathogenic mechanisms underlying NCLs are generally
unknown. Recent evidence suggests CLN proteins' involvement in cyto-
skeletal dynamics, sorting or recycling endosomes, including lysosomes
and autophagosomes and synaptic membrane trafﬁcking, and apoptosis
[9–16].
CLN8 belongs to the group of CLN proteins and is mutated in two
distinct clinical phenotypes: the progressive epilepsy with mental retar-
dation (EPMR), a juvenile-onset phenotypic variant [17], and a more
severe form that shares clinical and pathological similarities with the
late-infantile NCL variants (vLINCL), including CLN5-, CLN6- and CLN7-
associated diseases [1,18–20]. At least 24 different mutations, either
deletion or missense, are linked to CLN8 diseases and mostly to the
vLINCL form [1]. Using the naturally-occurring mnd (motor neuron
degeneration)mousemodel (Cln8mndmouse) exhibiting a disease pheno-
type similar to that of CLN8-vLINCL [17,21,22], numerous studies have
shown altered lipidmetabolism, oxidative and ER stresses, mitochondrial
dysfunction, defects in calcium homeostasis, inﬂammation and apoptosis
[23–29]. Changes in brain lipids and ER-stress responses inﬁbroblast cells
have been also reported in EPMR patients [30,31]. However, due to
the still undeﬁned CLN8 function, the primary defect underlying CLN8-
associated diseases remains an open question.
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286-amino acid (aa) residues and contains ﬁve-hydrophobic regions
corresponding to a TLC (TRAM-LAG1-CLN8) domain of 200 aa
(62–262), a luminal-oriented N-terminus and a functional C-terminal
ER-retrieval KKRP signal, likely facing the cytosolic side, for recycling be-
tween ER and ER-Golgi intermediate compartment (ERGIC) [1,17,22,32].
Most CLN8 mutations do not affect the protein localization at the ER
[20,22,33], suggesting that CLN8-deﬁciency in the ER may be responsible
for the onset of the disease. However, CLN8 is seen outside the ER in a
specialized subcompartment of the polarized epithelial CaCo2 cells [33],
in the Golgi, endosomes and lipid rafts of mouse ﬁbroblasts [34], as
well as in the proximity of plasma membrane of hippocampal neurons
[20,33]. In addition, CLN8 may interact with other CLN proteins such
as CLN2, CLN3, CLN5 and CLN6 in different subcompartments [34,36],
even if an in vivo conﬁrmation is still lacking and no interaction and
heterodimerization between CLN8 and CLN6, another ER-resident CLN
protein, are detected using different experimental approaches [37].
Although the precise function of CLN8 remains elusive, a potential role
in lipid homeostasis is supposed on its homology to the TLC family
and some evidence referring to its implication in sphingolipids' regula-
tion [24,25,32]. Moreover, CLN8 overexpression has been found to
induce cell proliferation and survival after a damaging insult [20].
To gain insight into CLN8 function and identify molecular partners,
we here thought to use a split-ubiquitin membrane yeast two-hybrid
(MYTH) screen which allows sorting out interactions in a membrane
environment. The conventional MYTH system relies on the fact that sev-
ered C-terminal (Cub) and N-terminal (Nub) halves of ubiquitin sponta-
neously reassemble to form a functional ubiquitin molecule [38]. We
then used a C-terminally Cub-tagged full-length CLN8 as a bait and an
N-terminally NubG-tagged human brain cDNA library as a prey to search
for CLN8 interactors through the MYTH system. These experimental
conditions permit the identiﬁcation of prey proteins, either membrane
or cytosolic proteins, with the N-terminal portion exposed to the cytosol,
thus excluding prey partners with a different topology like many CLN
proteins [1]. Our study reports the identiﬁcation of different binding
partners of CLN8 and especially refers to a group of six interacting
proteins, two of which supported herein by conﬁrmation assays, that
are involved in biologically relevant processes with potential links to
the NCL pathophysiology.
2. Materials and methods
2.1. Split-ubiquitin membrane based yeast two-hybrid assay
The split-ubiquitin membrane based yeast two-hybrid assay (MYTH)
was carried out in the version of DUALmembrane system Kit 2
(Dualsystems Biotech, Switzerland). For building CLN8-bait, the cod-
ing region of CLN8 was PCR ampliﬁed from SVPoly-CLN8, kindly
provided by Drs. L. Lonka and A.E. Lehesjoki (Neuroscience Center
and Folkhälsan Institute of Genetics, Biomedicum Helsinki, Universi-
ty of Helsinki, Finland), with primers containing SﬁI restriction sites
(Fw: 5′-GAATTCCCGGCCATTACGGCCATGAATCCTGCGAGCGATGGGG
G-3′, Rv: 5′-GGGAATTCGGCCGAGGCGGCCGGCCTCTTCTTCCGCAGCA
GCTG-3′). Polymerase chain reaction (PCR) fragments were cloned
into the pCCW and pCCW-STE vectors to yield, respectively, pCCW-
CLN8 and pCCW-STE-CLN8 plasmids encoding CLN8 baits fused to the
Cub-LexA-VP16 cassette (Dualsystems Biotech, Switzerland). To verify
the correct expression of baits and their eventual self-activation on the
reporter genes, each bait plasmid was transfected with the positive
pAI-Alg5 or negative pDL2-Alg5 control preys into the NMY32 yeast
strain [MATa his3delta200 trp1-901 leu2-3,112 ade2 LYS2::(lexAop)
4-HIS3 URA3::(lexAop)8-lacZ (lexAop)8-ADE2 GAL4] and the growth
on the triple and quadruple dropout media (SD-LTA, SD-LTH and
SD-LTHA) was analyzed. The human adult brain cDNA library was
constructed in the pNubGx plasmid (Dualsystems Biotech) to express
cDNAs fused to the C-terminus of NubG. Twenty-eight μg of the librarywas transformed into the NMY32 yeast expressing CLN8-bait and the
screening was carried out by means of the growth on the quadruple
dropout selection medium SD-LTHA. Colonies that were bigger and
with white color, likely expressing interactions, were re-streaked
on SD-LTHA medium with or without 5 mM 3-amino-1,2,4-triazole
(3-AT), a competitive inhibitor of His3-protein. The selected colonies
were screened further by the output of the third reporter gene, LacZ,
throughout the semiquantitative β-galactosidase assay. From colonies
developing the highest color, prey plasmid DNAs were isolated,
transformed into E. coli XL1blue for the ampliﬁcation and, ﬁnally, were
re-transfected into CLN8-bait yeast for a second round of screening on
SD-LTHAand SD-LTHA+5 mM3-ATmedia. Inserts of positive plasmids
were sequenced using primers for the pNubG-X vector chosen from
both ends of the inserts. Nucleotide sequences were compared to the
GenBank database using BLAST program available at the National Cen-
ter for Biotechnology Information.
2.2. β-Galactosidase assay
The semi-quantitative determination of the β-galactosidase ac-
tivity was performed as described by Stagljar et al. [38] with slight
modiﬁcations. Cells in 3 ml SD medium lacking tryptophan and leu-
cine were grown at 30 °C up to late exponential phase. Cells (0.5 OD600)
were pelleted, washed once in buffer Z [113 mM Na2HPO4, 40 mM
NaH2PO4, 10 mM KCl, and 1 mM MgCl2, (pH 7.0)] and suspended in
200 μl of buffer Z. After three freeze/thaw cycles, cells were incubated
with buffer Z (100 μl) containing 0.81% (v/v) 2-mercaptoethanol and
2-nitrophenyl-β-D-galactopyranoside (1 mg), for 5–15 min at 30 °C.
Blue color development was monitored by eye.
2.3. Plasmids for co-immunoprecipitation and co-localization experiments
For conﬁrmation assays, plasmids were generated by ampliﬁcation
of the full-length cDNAs followed by cloning into the appropriate
epitope-tagging vectors.
1) pFLAG-CMV4-CLN8: amplimers Fw 5′-CCCAAGCTTATGAATCCTGC
GAGCGATGGGG-3′ and Rv 5′-CCCAAGCTTCTATGGCCTCTTCTTCCG
CAGCAG-3′, HindIII restriction enzyme, pFLAG-CMV4 vector (Sigma)
2) pMyc-CMV3-CLN8: amplimers, Fw 5′-GGAATTCACCATGAATCCTG
CGAGCGATGG-3′ and Rv 5′-CCCAAGCTTCTATGGCCTCTTCTTCCGC
AGCAG-3′, BamHI-EcoRI restriction enzyme, pCMV3-Tag2A vector
(Stratagen)
3) pMyc-CMV3-VAPA or pFLAG-CMV4-VAPA: amplimers Fw 5′-CGG
GATCCACCATGGCGA AGCACGAGCAGA-3′ and Rv 5′-GGAATTCCT
ACAAGATGAATTTCCCTAGAA-3′, BamHI-EcoRI or BglII site (Klenow-
blunted) restriction enzymes, pCMV3-Tag2A or pFLAG-CMV4 vectors
4) pMyc-CMV3-GATE16 or pcDNA4-V5-GATE16: amplimers Fw 5′-C
GGGATCCACCATGAA GTGGTGTTCAAGG-3′ and Rv 5′-GGAATTCT
CAGAAGCCAAAAGTGTTCTCTC-3′, BamHI-EcoRI restriction enzyme,
pCMV3-Tag2A or pcDNA4-V5-HisA vectors (Invitrogen)
5) pCMV4-FLAG-GATE16: GATE16 cDNA was excised from pcDNA4-
V5-GATE16 plasmid with HindIII and EcoRI and cloned into pFLAG-
CMV4 digested with the same restriction enzymes
6) pcDNA3-CLN8: CLN8 cDNA was excised from SVPoly-CLN8 plasmid
with EcoRI and HindIII and cloned into pcDNA3 vector (Invitrogen)
restricted with the same enzymes.
All constructs were checked by DNA sequence analysis.
2.4. Production of a polyclonal antibody anti-CLN8
To produce a polyclonal antibody against a His-tagged peptide of the
C-terminal domain of human CLN8, the DNA region coding for aa's
238–286 of CLN8 was ampliﬁed from SVPoly-CLN8 plasmid, cleaved
with restriction enzymes (BamHI and HindIII), and ligated into the
pQE30 vector (Qiagen) to yield the pQE30-721-stop-CLN8 construct.
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denaturing conditions by using a HisTrap HP column and imidazole as
eluent, according to the manufacturer's instructions (GE Healthcare).
Fractions were analyzed by 14% SDS-PAGE and Coomassie brilliant
blue staining, and then dialyzed against 1X-PBS buffer. Immunization
of rabbits with the puriﬁed peptide was performed by Sigma-Genosys.
Finally, the polyclonal CLN8 antiserum (indicated as Ab-SG2489) was
afﬁnity puriﬁed using CNBr-activated Sepharose 4B beads coupled
with the same His-tagged-CLN8 peptide.
Histidine-tagged peptide: MRGSHHHHHHGSLTLIINPYWTHKKTQQLL
NPVDWNFAQPEAK SRPEGNGQLLRKKRP.
Amplimers: CLN8-nt721 5′-CGCGGATCCCTTACGCTAATCATTAAT
CCATAT-3′ and CLN8-RV-HindIII 5′-CCCAAGCTTCTATGGCCTCTTCTTC
CGCAGCAG-3′.
2.5. Cell culture and transfection
COS1 and HeLa cells were cultured in Dulbecco's Modiﬁed Eagle's
Medium (DMEM)-High Glucose (EuroClone), supplemented with 10%
fetal calf serum and 1% penicillin/streptomycin (EuroClone). Cells
were transiently transfected with plasmids using the PolyFect trans-
fection reagent, according to manufacturer's instructions (Qiagen).
2.6. Co-immunoprecipitation, immunoprecipitation and Western blotting
COS1 cells were transfected with plasmids encoding epitope-tagged
fusion proteins (FLAG-CLN8,Myc-VAPAorMyc-GATE16) orwith empty
vectors, for 60 h. For co-immunoprecipitation studies, transfected cells
were treated for 30 min with the cross-linking reaction buffer [1 mM
Dithiobis(succinimidyl propionate)/DSP in PBS], and reactionswere ter-
minated by washing once with ice-cold PBS and adding Tris-buffered
saline [25 mM Tris–HCl (pH 7.4), 140 mM NaCl, 3 mM KCl, 1 mM
CaCl2, 0.5 mM MgCl2]. Cells were harvested, solubilized in lysis buffer A
[10 mM phosphate (pH 7.4), 150 mM NaCl, 5 mM KCl, 2 mM EDTA,
2 mM EGTA, 0.5% Triton X-100, and protease inhibitors mixture] and
centrifuged at 16,000×g for 20 min at 4 °C to remove cell debris.
100 μg of proteins were precleared and incubated overnight at 4 °C
with 2 μg anti-FLAG or anti-c-Myc rabbit polyclonal antibodies (Sigma)
or anti-Ab-SG2486 antibody. Then, 20 μl of protein A/G PLUS-Agarose
was added and the mixture incubated at 4 °C for 1 h. Beads were rinsed
three times with ice-cold buffer A containing 0.1% Triton X-100 and
suspended in 2X Laemmli buffer for 30 min at 37 °C. Immunoprecipitates
and total lysates were resolved on 10% SDS-PAGE. Proteins transferred
onto PVDF membranes (Amersham Bioscience) were immunoblotted
with the anti-FLAG (1:6000) or anti-Mycmouse (1:3000)monoclonal an-
tibodies, or the Ab-SG2489 antibody (0.7 μg/ml). Immunocomplexes
were detected with HRP-conjugated anti-mouse or anti-rabbit secondary
antibodies using SuperSignal West Pico-Pierce.
2.7. Immunoﬂuorescence and immunohistochemical microscopy analyses
HeLa cells were grown at a low-density on poly-D-lysine-coated
coverslips andwere singly or doubly transfectedwith plasmids encoding
epitope-tagged fusion proteins (Myc-CLN8 and/or FLAG-VAPA or Myc-
CLN8 and/or FLAG-GATE16), for 24 h. Cells were ﬁxed with 4% parafor-
maldehyde, permeabilized with 0.1% Triton X-100 and blocked for
30 min with 5% NGS in PBS. For double immunostaining, primary
antibodies in blocking solution were incubated simultaneously overnight
at 4 °C, followed by a 2-h incubation with secondary antibodies. Primary
antibodies were rabbit polyclonal anti-Myc (1:600) andmousemonoclo-
nal anti-FLAGM2 (1:500) antibodies from Sigma, andmousemonoclonal
anti-PDI antibody (1:400) from Stressgen. Secondary antibodies were
anti-rabbit IgG-TRITC (1:100) and anti-mouse IgG-FITC (1:50) antibodies
from Chemicon and Immunological Sciences. Nuclei were stained with
4′,6-diamidino-2-phenylindole dihydrochloride/DAPI (Sigma). Immuno-
histochemical analyses involving animals were conducted in compliancewith protocols approved by the local animal use and care authorities.
Four-week-old C57BL/6J mice (n=5) were obtained from Harlan Italy
and Cln8mndmice (n=5) fromMario Negri Institute for Pharmacological
Research (Milan, Italy). Analyses were carried out using 4% PFA-ﬁxed
parafﬁn-embedded sections (5 μm) which were treated for antigen
retrieval as described previously [29]. For immunoperoxidase labelling,
cerebral cortical sections were blocked with 10% NGS plus 0.2% Triton
X-100 for 1 h and incubated overnight with the immunoafﬁnity puriﬁed
rabbit Ab-SG2489 antibody (1:50 in 1% NGS), followed by a 2-h incuba-
tion with biotin-conjugated secondary antibody (Vector Laboratories;
diluted 1:250 in 1% NGS). Immunopositive interactions were detected
with avidin-biotin peroxidase using a Vectastain Elite ABC standard kit
(Vector Laboratories) and diaminobenzidine. For double-labelling immu-
noﬂuorescence, brain tissue sections incubated with the anti-Ab-SG2489
antibody as above were treated with TRITC-labelled goat anti-rabbit IgG
(1:100) for 2 h, then re-blocked with 1% NDS plus 0.2% Triton X-100
before the incubation with the second primary antibody. Then, the poly-
clonal goat anti-VAPA antibody (1:50 in blocking solution, Santa Cruz
Biotechnology) was added for 2 h, followed by incubation with the sec-
ond secondary antibody, Alexia Flour 488 donkey anti-goat IgG (1:500,
Molecular Probes). Cell and tissue slideswere coverslipped in Vectashield
(Vector Laboratories, Burlingame, CA). Images were acquired with an
Axioskop 2 Zeiss microscope and edited with Adobe Photoshop software.
Control experiments were run for detection of speciﬁcity and lack
of crossreactivity demonstrating that unspeciﬁc staining was virtually
absent.3. Results
3.1. Split-ubiquitin membrane based yeast two-hybrid assay (MYTH)
Based on the presumed topology of CLN8 predicting ﬁve ER trans-
membrane domains and a cytosolic-oriented C-terminal ER retrieval
motif, we reasoned to use the split-ubiquitin MYTH assay that detects
interacting proteins in a membrane environment, either membrane or
cytosolic proteins [38]. The MYTH system utilizes the split of ubiquitin
into two halves, one half (Cub) fused to a bait protein and followed by
a transcription factor (TF) LexA-VP16, and the other half (NubG or
NubI, the last for control experiments) fused to a prey protein. Upon in-
teraction of bait and prey proteins, reconstitution of ubiquitin leads to
the proteolytic cleavage by ubiquitin-speciﬁc proteases of the TF that
entering into the nucleus activates reporter genes. We generated two
CLN8 baits in which the human full-length CLN8 cDNA was inserted
into two different bait vectors, pCCW-STE and pCCW (pCCW-STE-CLN8
and pCCW-CLN8), and both encoded CLN8 as fusion to the N-terminus
of Cub followed by the transcription factor LexA-VP16 (CLN8-Cub-
LexA-VP16) (Fig. 1A). The pCCW-STEwas used because the STE2 leader
sequence of the S. cerevisae increases protein expression of heterolo-
gous type I integral membrane proteins like CLN8 protein. Both CLN8
bait constructs were veriﬁed using the yeast ER-resident ALG5 protein
as a positive control prey (pAI-NubI-Alg5) or as a negative control
prey (pDL2-NubG-Alg5) in which an I13G mutation in NubG failed the
association with the Cub bait. The interaction resulting in reporter
gene activation was monitored throughout the NMY32 yeast growth
assay on dropout selection media. As shown in Fig. 1B, the pCCW-
STE-CLN8 plasmid reconstituted split-ubiquitin and activated reporter
genes as revealed by the growth on the triple and quadruple dropout
selection media (SD-LTA, SD-LTH and SD-LTHA) of pAI-NubI-Alg5
transformed yeast. By contrast, no colonies grew with the negative
control prey pDL2-NubG-Alg5 or when the pCCW-CLN8 bait plasmid
was used. These results demonstrate that the pCCW-STE-CLN8 was
properly expressed, inserted and oriented into the yeast membrane,
i.e. with its Cub-LexA-VP16-tag facing the cytoplasm, and could be
used to pull out potential CLN8 binding proteins from a human adult
brain cDNA library.
532 R. Passantino et al. / Biochimica et Biophysica Acta 1833 (2013) 529–5403.2. Screening of a human adult brain cDNA library by MITH
To identify CLN8 interacting proteins, the NMY32 yeast expressing
the pCCW-STE-CLN8 bait was transfected with 28 μg of a human adult
brain cDNA library constructed in the prey vector pNubGx. We screened
a sufﬁcient number of transformants (1.5×107) for being each potential
partner independently represented multiple times and used selection
criteria for restricting our analysis to more probable interacting clones.
We had the ﬁrst screen revealing six-hundred His+/Ade+ clones that
were further analyzed for LacZ positivity (LacZ+) by β-galactosidase
assay. From seventy-seven colonies having intense blue color, prey plas-
midswere extracted and subjected to a second round of screening on the
selective medium SD-LTHA+5 mM 3AT. Then, ﬁfty-two positive prey
plasmids were sequenced and analyzed with Blast program in the NCBI
GenBank database. The analysis provided genes that were each found
in multiple positive clones or in one positive clone. Totally thirty inde-
pendent geneswere identiﬁed as potential CLN8 partners with sequence
identity to proteins having known or unknown functions. According toER lumen
Cytoplasm
CLN8-Bait
NH2
A
TF (lexA-VP16)
Cub
Transmembrane domain
SD-LT
undiluted
1:10
1:100
undiluted
1:10
1:100
1 2 3 4B
SD-LTH
SD-LTA
undiluted
1:10
1:100
undiluted
1:10
4) pCCW-CLN8 + pAI-NubI-Alg5
3) pCCW-CLN8 + pDL2-NubG-Alg5
2) pCCW-STE-CLN8 + pAI-NubI-Alg5
1) pCCW-STE-CLN8 + pDL2-NubG-Alg5
SD-LTHA 1:100
Fig. 1. (A) Cartoon of the CLN8-bait construct showing a luminal N-terminal domain, a
TLC domain with ﬁve transmembrane alpha-helices and a cytosolic C-terminal domain
fused to the Cub-TF reporter cassette (Cub-LexA-VP16). (B) Analysis of CLN8-bait ex-
pressing yeast. CLN8 baits (pCCW-STE-CLN8 or pCCW-CLN8) were co-expressed with
the negative (pDL2-NubG-Alg5) or positive (pAI-NubI-Alg5) control prey plasmids
on the dropout selection media (SD-LT, SD-LTA, SD-LTH and SD-LTHA). Yeast cells
were spotted at the indicated densities. The pCCW-STE-CLN8 plasmid interacts with
the positive control prey as demonstrated by the growth under all selective conditions.their frequency of detection and biological functions, they were assem-
bled into four groups that are listed in Table 1. A group of them included
potential false positive proteins that are repeatedly isolated in theMYTH
cDNA library screening as indicated by the manufacturer (Dualsystems
Biotech, Switzerland). Two other groups consisted of prey proteins
with unknown functions that were frequently or infrequently isolated
and prey proteins with known functions that appeared only once in
the screen and have roles in protein synthesis and folding, structure
and function of mitochondria, nervous system development and axonal
regeneration (see Table 1). The fourth group encompassed six prey pro-
teins that were more frequently isolated, being represented two to six
times, thus suggesting to be more reliable interactors. These proteins
corresponded to VAPA, c14orf1/hERG28, STX8, GATE16, BNIP3 and
BNIP3L. Their cDNAs were isolated as full-length, except for cDNAs
encoding BNIP3 thatmissedN-terminal coding regions in all three clones
isolated. As will be discussed in greater detail in the appropriate session,
these proteins are implicated in biological functions that are of potential
interest for outlining CLN8 role(s), such as synthesis and transport of
lipids, endosomal and membrane trafﬁcking, autophagy/mitophagy
and apoptosis. However, since interactions may not likewise occur in
mammalian cells, to beginwith conﬁrmation studieswe here investigat-
ed two of these potential interactors, VAPA and GATE16, by carrying out
co-immunoprecipitation and co-localization assays in mammalian cells
and CNS tissues.
3.3. Characterization of endogenous and recombinant CLN8 proteins
CLN8 gene is predicted to encode a 286 amino acid protein [22],
which is found to dimerize when overexpressed in BHK21 cells [37].
Before investigating on CLN8 interactions, we analyzed the expres-
sion of the endogenous and recombinant CLN8 proteins in our
experimental conditions. COS1 cellswere transfectedwith two CLN8 con-
structs, an untagged (pcDNA3-CLN8) and a FLAG-tagged (pFLAG-
CMV4-CLN8) construct, or with empty vectors for 60 h, and Western
blotting were performed by using an anti-CLN8 antibody (Ab-SG2489,
generated in our laboratory) and an anti-FLAG antibody. Using the
Ab-SG2489 antibody (Fig. 2A), we detected two bands around 23 and
46 kDa in cell lysates corresponding to the endogenous (Lane 1), the
untagged-overexpressed (Lane 2), and the FLAG-tagged CLN8 protein
(Lane 3), this last migrating with slightly high-molecular-weights due to
the addition of FLAG epitope. Similar bands were detected by reprobing
the membrane with the anti-FLAG antibody (Fig. 2B, Lane 3). These
bands appear to correspond to a monomeric form and dimeric forms
resulting from dimerization of the endogenous and/or recombinant
proteins. Carrying out immunoprecipitation experiments, there was
that the anti-FLAG and anti-CLN8 (Ab-SG2489) antibodies precipitated
FLAG-tagged monomeric and dimeric forms from COS1 cells transfected
with pFLAG-CMV4-CLN8 plasmid (Fig. 2C, Lanes 3 and 4). In addition,
Ab-SG2489 antibody speciﬁcity was analyzed by immuonoperoxidase
staining of cerebral cortical sections from 4-week-old Cln8mnd and
C57BL/6J control mice. The Cln8mnd mutation (267–268insC) pre-
dicts a truncated protein [17], which could not be detected by our an-
tibody. As shown in Fig. 3, the cerebral cortex of the control mouse
was heavily labelled with the antibody (A and C), whereas that of
the Cln8mnd mouse was virtually devoid of staining (B and D). These re-
sults demonstrate that CLN8was overexpressed and immunoprecipitated
fromCOS1 cells and the newly generated antibody speciﬁcally recognized
the endogenous and recombinant CLN8proteins, bothmonomeric anddi-
meric forms, and was suitable for immunohistochemical analysis.
3.4. Co-immunoprecipitation assay between CLN8 and VAPA or GATE16
To verify CLN8 interactions with VAPA or GATE16 by co-
immunoprecipitation (co-IP) experiments, we decided to use recom-
binant proteins produced in COS1 cells. Therefore, COS1 cells were co-
transfected with plasmids encoding epitope-tagged proteins Myc-VAPA
Table 1
List of proteins identiﬁed as binding partners of CLN8p in a split-ubiquitin MYTH screen of human adult brain cDNA library.
Gene ID Description Biological Process
Prey proteins with known functions, more frequently isolated
VAPA 9218 Vesicle-associated membrane protein-associated protein A Lipid metabolism/cellular membrane fusion
c14orf1 11161 Chromosome 14 open reading frame 1/hERG28 Sterol biosynthesis
STX8 9482 Syntaxin 8 Late endosome trafﬁcking
GATE16 11345 Golgi-associated ATPase enhancer of 16 kDa/GABARAPL2 Autophagy/Golgi vesicular transport/protein transport
BNIP3 664 BCL2/adenovirus E1B 19 kDa interacting protein 3 or NIP3 Autophagy/mitophagy/apoptosis
BNIP3L 665 BCL2/adenovirus E1B 19 kDa interacting protein 3-like or NIX Autophagy/mitophagy/apoptosis
Prey proteins with known functions, infrequently isolated
PDIA6 10130 Protein disulﬁde isomerase family A, member 6 Protein folding
RTN4 57142 Reticulon 4 Nervous system development/axonal regeneration
ARL6IP5 10550 ADP-ribosylation-like factor 6 interacting protein 5 L-Glutamate transport/cell differentiation
CD9 928 CD9 molecule Cell adhesion
MTX1 4580 Metaxin 1 Protein transport/protein targeting to mitochondrion
NDRG2 57447 NDRG family member 2 Signal transduction/cell differentiation
TUBB4 10382 Tubulin, beta 4 Microtubule-based movement
CYB5B 80777 Cytochrome b5 type B (outer mitochondrial membrane) Electron transport chain
RRP15 51018 Ribosomal RNA processing 15 homolog (S. cerevisiae) Protein binding
PTPRN 5798 Protein tyrosine phosphatase, receptor-type N Protein dephosphorylation/Cytokine signalling
Prey proteins with known functions, potential false positives
GPM6B 2824 Glycoprotein M6B Nervous system development/cell differentiation
SELK 58515 Selenoprotein K Oxidative stress
SPCS2 9789 Signal peptidase complex subunit 2 homolog (S. cerevisiae) Signal peptide processing
PLP1 5354 Proteolipid protein 1 Structural constituent of myelin sheath
UBC 7316 Ubiquitin C Protein degradation/cell cycle and repairing
PLP2 5355 Proteolipid protein 2 (colonic epithelium-enriched) Ion transport/chemotaxis/cytokine signalling
Prey proteins with unknown functions
YIPF6 86451 Yip1 domain family, member 6 Unknown
ZUFSP 221302 Zinc ﬁnger with UFM1-speciﬁc peptidase domain Unknown
TMEM11 8834 Transmembrane protein 11 Unknown
TMEM14A 28978 Transmembrane protein 14A Unknown
TMEM107 84314 Transmembrane protein 107 Unknown
TMEM128 85013 Transmembrane protein 128 Unknown
TMEM134 80194 Transmembrane protein 134 Unknown
TMEM147 10430 Transmembrane protein 147 Unknown
Interactors identiﬁed multiple times are shown in bold. Potential false positives match proteins that are repeatedly identiﬁed throughout the split-ubiquitin MYTH system
(www.dualsystems.com).
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were either treated or untreated with the reversible membrane-
permeable cross-linker DSP, which stabilizes protein-protein inter-
actions. Cells were lysed with 0,5% Triton X-100 and the clariﬁed
lysate was used as a solubilized cell extract in the co-IPs. Western
analyses were performed with either anti-Myc or anti-FLAG mono-
clonal antibodies. Inputs of overexpressed proteins in 10% of cell
lysates are shown in Fig. 4A and B (Lanes 2–5). When anti-Myc anti-
body was used to pull downMyc-VAPA or Myc-GATE16, it was found
that FLAG-CLN8monomeric and dimeric forms co-immunoprecipitated
with Myc-VAPA (Fig. 4A, Lane 7) or Myc-GATE16 (Fig. 4A, Lane 9)
from DSP-treated cell extracts; whereas, only FLAG-CLN8 monomer
immunoprecipitated with Myc-VAPA (Fig. 4A, Lane 8) but not with
Myc-GATE16 (data not shown) from DSP-untreated cell extracts. In
the reverse co-IP, using anti-FLAG antibody to pull down FLAG-CLN8,
both Myc-VAPA and Myc-GATE16 co-immunoprecipitated with FLAG-
CLN8 from DSP-treated cells (Fig. 4B, Lanes 7 and 9), and neither
Myc-VAPA (Fig. 4B, Lane 8) nor Myc-GATE16 (data not shown) were
pulled down by FLAG-CLN8 from DSP-untreated cells. In control exper-
iments, no signals were detected when DSP-treated cells were singly
transfectedwith FLAG-CLN8,Myc-VAPAorMyc-GATE16 andprecipitat-
ing antibodies were omitted (Fig. 4A and B, Lanes 6). Furthermore,
using the immunoafﬁnity puriﬁed anti-CLN8 (Ab-SG2489) antibody,
we immunoprecipitated Myc-VAPA from DSP-treated cells as expected
(Fig. 4C, Lane 3), and in the reverse co-IP, both monomeric and dimeric
forms of FLAG-CLN8were pulled down byMyc-VAPA (data not shown).
These results conﬁrm VAPA and GATE16 as binding partners of CLN8
which presumably interacted in a favoured dimeric conformation. On
the other hand, the strict dependence on cross-linking conditions tostabilize their associations suggests their weak and/or transient nature.
However, in the absence of DSP treatment, it cannot be excluded
that experimental conditions, such as the presence of detergent,
could have interfered with protein structures and so with protein
associations.
3.5. Co-localization of CLN8 with VAPA or GATE16
To further investigate the interaction between CLN8 and VAPA or
GATE16, we examined their co-localization by immunoﬂuorescence mi-
croscopy. VAPA, like CLN8, is an integralmembrane proteinmainly locat-
ed to the ER [22,33,39]; GATE16, an ubiquitin-like lowmolecular weight
protein, is present on the Golgi complex to regulate the ER-Golgi and
intra-Golgi transport [40], but also on the autophagosome membranes
[41,42]. Double immunoﬂuorescence was carried out in HeLa cells
transiently transfected with expression vectors encoding Myc-tagged
CLN8 and FLAG-tagged VAPA (Fig. 5D–F) or Myc-tagged CLN8 and
FLAG-tagged GATE16 (Fig. 5J–L), for 24 h. In addition, cells singly
transfected with either of plasmids (Fig. 5G–I) or with empty vectors
(Fig. 5M–N) were analyzed as controls of the expression of proteins.
We veriﬁed that HeLa cells singly transfected with Myc-tagged CLN8
exhibited a typical reticular staining pattern which largely coincided
with PDI, an ER resident protein, thus conﬁrming that transfection did
not affect CLN8 localization (Fig. 5A–C). By comparing single to double
transfections, no apparent change in the localization of Myc-tagged
CLN8 was also noted (Fig. 5A and G vs. D and J). In cells transfected
with Myc-tagged CLN8 and/or FLAG-tagged VAPA, there was that the
overall distribution of these two proteins was quite similar (Fig. 5D and
E vs. G and H), and an extensive overlapping signal emerged in yellow
Fig. 3. Immunoperoxidase staining of cerebral cortices from C57BL/6J and CLN8mnd
mice with anti-CLN8 antibody (Ab-SG2489). (A and C) Representative images of
C57BL/6J sections showing immunopositive cells for CLN8. (B and D) Representative
images of CLN8mnd sections in which no immunoreactivity for CLN8 is detected. Images
are representative of ﬁve stained sections per mouse (n=5 mice/group). Size bars
equal 200 μm (A and B) and 25 μm (C and D).
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Fig. 2.Western blot analysis of the endogenous and recombinant CLN8 proteins. (A) Lysates of COS1 cells transfected with empty vectors pcDNA3 and pFLAG-CMV4 (Lanes 1, low
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534 R. Passantino et al. / Biochimica et Biophysica Acta 1833 (2013) 529–540colour in doubly transfected cells (Fig. 5F), strongly supporting their
interaction at the ER. The analysis of cells overexpressing both Myc-
tagged CLN8 and FLAG-tagged GATE16 showed that CLN8 co-localized
with GATE16 in a juxtanuclear region and in a few punctate structures
which resembled vesicle structures (Fig. 5J–L). Note that some punctate
structures stained positive only for FLAG-tagged GATE16 (arrows and
inset in Fig. 5L). No difference in labelling was apparent when cells
transfected with GATE16 alone or together with CLN8 were compared
(Fig. 5I vs. K). Thus, co-localization, albeit partial, was also observed be-
tween CLN8 and GATE16.
3.6. Immunohistochemical analysis of CLN8 and VAPA in CNS tissues
Given that CLN8 is supposed to function in lipid homeostasis and
VAPA importantly contributes to lipid transport and synthesis [39],
their co-localization was further assessed in the murine cerebral
cortex, hippocampus, cerebellum and spinal cord, where both pro-
teins are expressed [43,44]. Double immunoﬂuorescence staining
was carried out using the anti-CLN8 (Ab-SG2489) antibody (red)
and anti-VAPA antibody (green) (Fig. 6). All tissues exhibited an in-
tense punctate staining of cell bodies and, occasionally, along prox-
imal neuritic processes for both CLN8 (Fig. 6Aa–d) and VAPA
(Fig. 6Ae–h). As visualized by yellow colour in the merged images,
signals of these proteins were largely overlapping in the cerebral
cortical (Fig. 6Ai) and hippocampal neurons (Fig. 6Aj), cerebellar
Purkinje and granule cells (Fig. 6Ak) and lower motor neurons of
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were also visible, especially in the cerebral cortex (Fig. 6Ai). In this
set of experiments, tests were run to exclude the cross-reactivity
by using antibodies of the same species. As shown by representative
cerebellar sections, no cross-reactivity was detectable by omitting
the primary antibodies (Fig. 6Ba-a1), or by excluding the second
primary antibody, the anti-VAPA antibody (Fig. 6Bb1 vs. Bb). In par-
ticular, double labelling experiments with the omission of the
anti-VAPA antibody demonstrated CLN8 staining of sections visual-
ized with the primary secondary antibody (Fig. 6Bb) and no staining
with the second secondary antibody added after re-blocking of tissue
sections (Fig. 6Bb1), thus indicating that no interference occurred in
our experiments. In addition, the staining patterns of the individual
proteins were nearly identical to those obtained by double labelling
sections (Fig. 6Bc and Bc1 vs. Ac and Ag). Therefore, these results
support the association of CLN8 with VAPA in the correct neuronal
contexts and at physiologically relevant expression levels.4. Discussion
The biological function of CLN8 protein and the pathophysiology
of CLN8 deﬁciency in NCL-associated diseases are largely unknown.
Using the split-ubiquitin membrane-based yeast two-hybrid (MYTH)
system, we identiﬁed a group of protein partners (VAPA, c14orf1/
hERG28, STX8, GATE16, BNIP3 and BNIP3L) that potentially interact
with CLN8 and so may provide insights into the functional network of
CLN8 and themolecular mechanism underlying CLN8 pathology. To pre-
serve the native three-dimensional structure of CLN8 protein, including
both membrane and non-membrane regions, the full-length form was
used as bait for the screening of a human adult brain cDNA library
through the MYTH system. These interactors were selected under strin-
gent selection conditions using quadruple dropout selection media
together with alpha-galactosidase activity test, and the frequency of
their detectionwas undertaken as a parameter of speciﬁcity and reliabil-
ity of the screen. Two of them, VAPA and GATE16, were conﬁrmed as
Fig. 5. Co-localization of CLN8 with VAPA or GATE16. HeLa cells were singly or doubly transfected with vectors encoding Myc-tagged CLN8 and/or FLAG-tagged VAPA or Myc-tagged
CLN8 and/or FLAG-tagged GATE16. Twenty-four hours post-transfection, cells were ﬁxed, permeabilized and processed for immunoﬂuorescence using the anti-PDI (ER marker),
anti-Myc and anti-FLAG antibodies, followed by appropriate secondary antibodies. (A-C and G-I) Representative images of single transfected cells. (B–F and J–L) Representative
images of double transfected cells. Yellow in merged images represents co-localizations of proteins. Inset in (L) shows a high magniﬁcation view of CLN8 and GATE16
co-localization and the only GATE16-positive punctate structures (indicated by arrows). (M, N) Cells transfected with empty vectors and stained with anti-Myc and anti-FLAG an-
tibodies, and counterstained with DAPI (blue) to detect nuclei; no staining is visible. Images are representative of three independent experiments. Scale bar, 50 μm.
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assays in mammalian cells, and CLN8-VAPA co-localization was also
detected in CNS tissues. For these experiments, it was produced a new
C-terminal-oriented CLN8 antibody that detected endogenous and
recombinant CLN8 proteins, including its 46 kDa dimer previously de-
scribed [37], speciﬁcally stained brain and spinal cord sections and, as
expected, failed to recognize the mutated CLN8 in the Cln8mnd cerebral
cortex. In the MYTH screen, another group of prey partners uncovering
signiﬁcant biological processes such as protein synthesis and folding,mi-
tochondrial organization and neuronal development and plasticity, was
nonetheless infrequently identiﬁed and so excluded from our analysis.
To analyze the potential biological meaning of CLN8 partners, we as-
sembled an hypothetic interactome map in Fig. 7, which incorporates
bait-prey interactions together with selected biologically relevantconnections of the identiﬁed six prey proteins taken from the Human
Protein Reference Database (http://www.hprd.org/index_html). In the
map, each partner bridges more proteins in a given pathway, some
partners share biological categories and three are connected with each
other. This analysis highlights four main biological process categories:
synthesis and transport of lipids (c14orf1/hERG28 and VAPA), vesicular/
membrane trafﬁcking (VAPA, STX8 and GATE16), autophagy/mitophagy
clearance (GATE16, BNIP3 and BNIP3L) and apoptosis (BNIP3 and
BNIP3L). These unforeseen results certainly need further conﬁrma-
tion experiments; however, they indicate possible functional mod-
ules of CLN8 that warrant closer attention.
The possible implication of CLN8 in the lipid biosynthesis and protein/
lipid transport is a current subject of investigation. As a member of the
family of TLC (TRAM-Lag1p-CLN8)-domain homologues [32], CLN8 is
Fig. 6. Co-localization of CLN8 and VAPA in the adult mouse CNS tissues. Tissue sections from 4-week-old C57BL/6J mice were processed for double-labelling immunoﬂuorescent
analyses of CLN8 and VAPA using the immunoafﬁnity puriﬁed Ab-SG2489 and anti-VAPA antibodies. (A) Representative images showing CLN8 (a–d) and VAPA (e–h) immunore-
activities in the indicated tissues. Extensive co-localization in yellow colour (merge) is seen in the cerebral cortical neurons (i), hippocampal pyramidal cells (j), cerebellar granules
and Purkinje cells (k), and lower motor neurons in the ventral horn of the spinal cord (l). Arrows point to positive signals over proximal processes. (B) Representative images of
double staining control experiments showing cerebellar sections in which both primary antibodies (a and a1) or only the second primary antibody/anti-VAPA antibody (b and b1)
were omitted and single staining reactions with Ab-SG2489 (c) or anti-VAPA (c1) antibodies were performed. Images are representative of four stained sections. py, hippocampal
pyramidal cells; pu, cerebellar Purkinje cells; gr, cerebellar granular layer; ah, anterior horn of the spinal cord. Scale bar, 50 μm.
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Fig. 7. Potential interaction networks for CLN8. In the map, four biologically relevant networks consisting of proteins involved in synthesis and transport of lipids, vesicular/mem-
brane trafﬁcking, autophagy/mitophagy and apoptosis are shown. Arrows indicate associations of CLN8 bait and six preys identiﬁed by the MYTH screen and lines indicate selected
connections of the prey partners extracted from the Human Protein Reference Database. Dotted arrows indicate two additional preys that were, respectively, characterized as less
and more frequently preys: the isoform tubulin B4, a direct partner of GATE16/GABARAPL2, and the unknown mitochondrial inner-membrane protein TMEM11 interacting with
BNIP3 and BNIP3L. VAMPs stands for vesicle-associated membrane protein (VAMP)/synaptobrevin proteins.
538 R. Passantino et al. / Biochimica et Biophysica Acta 1833 (2013) 529–540supposed to function in synthesis, transport and sensing of lipids. Stud-
ies also suggest that CLN8 might impact ceramide de novo synthesis
[35] or bind ceramide and galactosylceramide [24]. On the other hand,
CLN8 deﬁciency is associated with alterations in sphingolipid raft com-
position [24] and myelin galactolipids in the mnd mouse model [25],
and changes in brain sphingolipids, cholesterol and phospholipids of
EPMR patients [30]. How CLN8 may inﬂuence lipid/sphingolipid ho-
meostasis, having for instance a catalytic activity or accomplishing
transport events, is thus a crucial issue. It is quite interesting that
VAPA and likely c14orf1/hERG28 are involved in the lipid synthesis/
trafﬁcking and lipid-dependent segregation of proteins in the secretory
pathway and they were identiﬁed as binding partners of CLN8 in our
study. c14orf1/hERG28 protein is poorly characterized but its yeast
hortologue reveals an interesting link to sterol synthesis and contribu-
tion to microdomain membrane assembly and function [45,46]. The
conﬁrmation of CLN8 and c14orf1/hERG28 interaction might impart
clues to CLN8 function and expand previously unknown aspects of
c14orf1/hERG28. Some our data, not presented herein, actually support
their direct contact by revealing cellular co-localization at the ER.
We ﬁnd of particular interest the CLN8-VAPA interaction in view of
the roles played by VAPA, an integral membrane protein of the VAMP
(vesicle-associated membrane protein) protein family. VAPA may be-
have as a docking site for different cytosolic lipid-binding proteins at
the ER, thus participating in the synthesis/trafﬁcking of sphyngolipids,
phospholipids and cholesterol [39,47–49]. Furthermore, it may act to
maintain intracellularmembrane structures such as the ER, by interacting
with cytoskeletal components and mediating membrane trafﬁcking
[50–52]. New evidence suggests that VAPA binds to ORP1L and, in trans,
to Rab7-RILP receptor for regulating cholesterol-dependent late endo-
some trafﬁcking, and perturbation of VAPA-ORP1L association by high
cholesterol levels may cause clustering of late endosomes that typically
occurs in Niemann-Pick type C disease, Gaucher disease and other LSDs
[53]. Recently, an interaction between CLN3 and Rab7-RILP has been
reported to inﬂuence the location of the late endosomes/lysosomes possi-
bly via associations to cytoskeletal motor proteins [12]. VAPA and CLN8
are both mainly located to the ER and ERGIC compartments and, outside
the ER, they also show a similar pattern of distribution at the Golgi appa-
ratus, recycling endosomes andplasmamembrane [39]. Interestingly, this
spare location of VAPA facilitates non-vesicular lipid trafﬁcking throughmembrane contact sites (MCS) between ER and other organelles [49].
In the Cln8mnd mouse, alterations in lipid and protein transport and
ER/mitochondria Ca2+ tunneling are linked to defects in mitochondria-
associated ER-membranes (MAMs) [23,28], whether otherMCS are failed
in CLN8 deﬁciency is presently unknown. Our results prove CLN8 and
VAPA co-localization in a typical ER reticular network when over-
expressed in cells, and additionally demonstrate that endogenous pro-
teins are located in close spatial proximity within the brain and spinal
cord tissues. These results and those of co-IP assays in mammalian cells
strongly support their association detected by library screening. Although
further studies are needed to establish the binding sites and the precise
subcellular localization, we may suspect a functional cooperation be-
tween CLN8 and VAPA proteins. Our data from co-IPs indeed suggest
that CLN8 dimerization might facilitate interaction with VAPA.
Another interesting outcome of our analysis is the connection of CLN8
binding partners to the vesicular/membrane trafﬁcking. Rab GTPases and
SNAREproteins alongwith the ATPases-associatedNSF are key regulators
of all vesicle fusion events in the endocytic pathway [54]. It has been
already mentioned that VAPA participates to the late vesicle fusions
throughRab7, but it also regulates SNARE-mediated ER-Golgi vesicle traf-
ﬁc and contributes to the presynaptic SNARE complex formation by bind-
ingVAMP/synaptobrevin family and SNAP-25 [39,50,51]. Other twoCLN8
interacting proteins are linked to this biological category: syntaxin
8 (STX8) that is a proper t-SNARE of the post-Golgi endosomal compart-
ment acting in late endosome fusion [55], andGATE16 that interactswith
NSF and Golgi v-SNARE GOS-28 to modulate intra-Golgi transport [40],
but also functions in autophagic processes [41,42]. Interestingly, the
GATE16 homologous GABARAP together with NSF regulates GABAA
receptor transport, anchoring and clustering [56], and GABA neurons
are primary affected in CLN8-deﬁciency mice and in some other NCLs
[57].We here conﬁrmed CLN8-GATE16 interaction by co-IPs and a partial
cellular co-localization, whereas CLN8-STX8 interaction was not investi-
gated in this study. These observations raise the question if CLN8 could
participate to the processes governing the endocytic pathway, including
synaptic vesicle trafﬁcking. Other NCL-associated CLN proteins show to
have roles in sorting or recycling endosomes [9–14], as well as, some of
them are expressed in synaptic compartments suggesting an additional
function, beside the one at the endolysosomal compartments [8,58,59].
A defective synaptic vesicle protein cysteine-string protein-α (CSPα)
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the autosomal-dominant adult-onset Kufs disease [CLN4/DNAJC5, 3,4].
CLN8 protein is also found to extend toward the neuronal periphery,
thus having a probable vesicular localization in neurons [33]. As amatter
of fact, we report CLN8 staining in cell bodies and neurites of different
CNS tissues (Fig. 6), and in murine retinal axon terminals (unpublished
data), which suggest a precise functional role in neurons.
As a member of LC3/GABARAP/GATE16 protein family [41], GATE16
also participates to the autophagosome maturation [42]. GATE16 seems
to be involved in constitutive transport under normal conditions and in
autophagic processes following stresses during which the typical punc-
tate structures expressing GATE16 increase in number [41]. We found
that GATE16 and CLN8 located together at the perinuclear region and a
few vesicle-like structures.We presently cannot establish their exact sub-
cellular co-localization, whose appearance is more reminiscent of the
Golgi apparatus. Our results also suggest a weak and/or transient
association of CLN8 and GATE16, being co-immunoprecipitated only
under cross-linking conditions. It is well known that the cellular state
and post-translational modiﬁcations inﬂuence the association of proteins
during endocytic transport and autophagosome biogenesis. Further stud-
ies could certainly clarify the nature of CLN8 and GATE16 interaction.
It is noteworthy that GATE16 associateswith two other CLN8 partners
isolated in this study, BNIP3 and BNIP3L that belong to the BH3-only
proteins of Bcl-2 family and function in selective autophagy and apoptosis
(see map in Fig. 7). GATE16, BNIP3 and BNIP3L interact each other and
with p62 and NBR1 for selectively degrading ubiquitinated substrates
and organelles [60,61]. In addition, BNIP3 and BNIP3Lmay serve as selec-
tive autophagy receptors for the mitochondrial clearance (mitophagy)
[61,62], ormay act as promoters of apoptosis following their translocation
from cytosol to mitochondria or Ca2+ mobilization between ER and
mitochondria [62]. Selective autophagy has lately gained much interest
in that it may promote a “quality control” by removing aggregates or
nonfunctional mitochondria that occur in many neurodegenerative dis-
eases and LSDs [63]. Impaired autophagic events are suggested to arise
in NCL-associated cathepsin D-, CLN6- and CLN3-deﬁciencies, the latter
likely exhibiting abnormal mitochondrial clearance [15,16,64–66]. On
the other hand, apoptosis occurs in NCL pathology, including CLN8 dis-
ease [13,24,27,29].
This study is the ﬁrst protein-protein interaction survey on the CLN8
protein that reveals multiple interaction partners and potential connec-
tions of CLN8 to four functional categories: lipid synthesis and trafﬁc,
vesicular/membrane trafﬁc, autophagy/mitophagy and apoptosis. The
ubiquitous expression of CLN8 in brain tissues and peripheral organs –
such as liver, spleen and heart – would imply multifunctional roles.
Our ﬁndings are in agreement with the current research proﬁling simi-
lar functional categories for someCLNproteins and their involvement in
brain pathology of NCL diseases. A new study reports that CLN8may be
a modiﬁer gene for the non-neuronopathic type-1 Gaucher disease and
its induction likely protects cells from lipid accumulation and damage in
these patients [67], suggesting an important role of CLN8 in a non-
neurodegenerative disease. It is very peculiar that mutations in CLN8
gene only lead to neuronal vulnerability in CLN8-associated NCL dis-
eases, albeit it localizes to neuronal and noneuronal cells. Furthermore,
phenotypic divergence characterizes these diseases, being the vLINCL
and Cln8mnd forms more severe than EPMR disease. If different muta-
tions can reﬂect differences in protein function and clinical severity is,
of course, an interesting question for future studies. Although many
challenges lie ahead to deﬁne CLN8 interactions, the interactome iden-
tiﬁed provides a framework upon which to expand and deepen our
knowledge on its biological roles and pathomechanisms underlying
disease-associated CLN8mutations.
Acknowledgements
We would like to thank Drs. Liina Lonka and Anna-Elina Lehesjoki
(Neuroscience Center, Dept. Medical Genetics and Folkhälsan Instituteof Genetics, Helsinki, Finland) for providing us SVPoly-CLN8. We also
thankDr. G. Cassata andMs. A. Cusimano (Istituto Zooproﬁlattico, Paler-
mo, Italy) for help in performing experiments with animals in some
studies, and Dr. P. Bigini (Mario Negri Institute for Pharmacological Re-
search, Milan, Italy) for providing the Cln8mnd mice. This work was
supported by “PNR-CNR Aging Program 2012-2014”, Ministeri della
Salute, del Lavoro e Politiche Sociali and by MIURFIRB/RBRN07BMCT.
The authors declare no competing ﬁnancial interests.References
[1] M. Kousi, A.E. Lehesjoki, S.E. Mole, Update of the mutation spectrum and clinical
correlations of over 360 mutations in eight genes that underlie the neuronal
ceroid lipofuscinoses, Hum. Mutat. 33 (2012) 42–63.
[2] A. Jalanko, T. Braulke, Neuronal ceroid lipofuscinoses, Biochim. Biophys. Acta
1793 (2009) 697–709.
[3] L. Nosková, V. Stránecký, H. Hartmannová, A. Přistoupilová, V. Barešová, R. Ivánek,
H. Hůlková, H. Jahnová, J. van der Zee, J.F. Staropoli, K.B. Sims, J. Tyynelä, C. Van
Broeckhoven, P.C. Nijssen, S.E. Mole, M. Elleder, S. Kmoch, Mutations in DNAJC5,
encoding cysteine-string protein alpha, cause autosomal-dominant adult-onset
neuronal ceroid lipofuscinosis, Am. J. Hum. Genet. 89 (2011) 241–252.
[4] B.A. Benitez, D. Alvarado, Y. Cai, K. Mayo, S. Chakraverty, J. Norton, J.C. Morris, M.S.
Sands, A. Goate, C. Cruchaga, Exome-sequencing conﬁrms DNAJC5 mutations as
cause of adult neuronal ceroid-lipofuscinosis, PLoS One 6 (2011) e26741.
[5] K.R. Smith, J. Damiano, S. Franceschetti, S. Carpenter, L. Canafoglia, M. Morbin, G.
Rossi, D. Pareyson, S.E. Mole, J.F. Staropoli, K.B. Sims, J. Lewis, W.L. Lin, D.W.
Dickson, H.H. Dahl, M. Bahlo, S.F. Berkovic, Strikingly different clinicopathological
phenotypes determined by progranulin-mutation dosage, Am. J. Hum. Genet. 90
(2012) 1102–1107.
[6] J. Bras, A. Verloes, S.A. Schneider, S.E. Mole, R.J. Guerreiro, Mutation of the parkin-
sonism gene ATP13A2 causes neuronal ceroid-lipofuscinosis, Hum. Mol. Genet. 21
(2012) 2646–2650.
[7] J.F. Staropoli, A. Karaa, E.T. Lim, A. Kirby, N. Elbalalesy, S.G. Romansky, K.B.
Leydiker, S.H. Coppel, R. Barone, W. Xin, M.E. MacDonald, J.E. Abdenur, M.J.
Daly, K.B. Sims, S.L. Cotman, A homozygous mutation in KCTD7 links neuronal
ceroid lipofuscinosis to the ubiquitin–proteasome system, Am. J. Hum. Genet.
91 (2012) 202–208.
[8] A.L. Getty, D.A. Pearce, Interactions of the proteins of neuronal ceroid
lipofuscinosis: clues to function, Cell. Mol. Life Sci. 68 (2011) 453–474.
[9] K. Luiro, K. Yliannala, L. Ahtiainen, H. Maunu, I. Järvelä, A. Kyttälä, A. Jalanko, In-
terconnections of CLN3, Hook1 and Rab proteins link Batten disease to defects
in the endocytic pathway, Hum. Mol. Genet. 13 (2004) 3017–3027.
[10] A.L. Getty, J.W. Benedict, D.A. Pearce, A novel interaction of CLN3 with nonmuscle
myosin-IIB and defects in cell motility of Cln3(−/−) cells, Exp. Cell Res. 317
(2011) 51–69.
[11] J.W. Benedict, A.L. Getty, T.M. Wishart, T.H. Gillingwater, D.A. Pearce, Protein
product of CLN6 gene responsible for variant late-onset infantile neuronal ceroid
lipofuscinosis interacts with CRMP-2, J. Neurosci. Res. 87 (2009) 2157–2166.
[12] K. Uusi-Rauva, A. Kyttälä, R. van der Kant, J. Vesa, K. Tanhuanpää, J. Neefjes, V.M.
Olkkonen, A. Jalanko, Neuronal ceroid lipofuscinosis protein CLN3 interacts with
motor proteins and modiﬁes location of late endosomal compartments, Cell.
Mol. Life Sci. 69 (2012) 2075–2089.
[13] P. Wang, W. Ju, D. Wu, L. Wang, M. Yan, J. Zou, B. He, E.C. Jenkins, W.T. Brown, N.
Zhong, A two-dimensional protein fragmentation-proteomic study of neuronal
ceroid lipofuscinoses: identiﬁcation and characterization of differentially expressed
proteins, J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 879 (2011) 304–316.
[14] E. Fossale, P. Wolf, J.A. Espinola, T. Lubicz-Nawrocka, A.M. Teed, H. Gao, D.
Rigamonti, E. Cattaneo, M.E. MacDonald, S.L. Cotman, Membrane trafﬁcking and
mitochondrial abnormalities precede subunit c deposition in a cerebellar cell
model of juvenile neuronal ceroid lipofuscinosis, BMC Neurosci. 5 (2004) 57.
[15] Y. Cao, J.A. Espinola, E. Fossale, A.C. Massey, A.M. Cuervo, M.E. MacDonald, S.L.
Cotman, Autophagy is disrupted in a knock-in mouse model of juvenile neuronal
ceroid lipofuscinosis, J. Biol. Chem. 281 (2006) 20483–20493.
[16] Y. Cao, J.F. Staropoli, S. Biswas, J.A. Espinola, M.E. MacDonald, J.M. Lee, S.L. Cotman,
Distinct early molecular responses to mutations causing vLINCL and JNCL presage
ATP synthase subunit C accumulation in cerebellar cells, PLoS One 6 (2011) e17118.
[17] S. Ranta, Y. Zhang, B. Ross, L. Lonka, E. Takkunen, A. Messer, J. Sharp, R. Wheeler,
K. Kusumi, S. Mole, W. Liu, M.B. Soares, M.F. Bonaldo, A. Hirvasniemi, A. de la
Chapelle, T.C. Gilliam, A.E. Lehesjoki, The neuronal ceroid lipofuscinoses in
human EPMR and mnd mutant mice are associated with mutations in CLN8,
Nat. Genet. 23 (1999) 233–236.
[18] S. Ranta, M. Topcu, S. Tan, H. Tegelberg, A. Ustübütün, I. Saatci, A. Dufke, H.
Enders, K. Pohl, Y. Alembik, W.A. Mitchell, S.E. Mole, A.E. Lehesjoki, Variant late
infantile neuronal ceroid lipofuscinosis in a subset of Turkish patients is allelic
to Northern epilepsy, Hum. Mutat. 23 (2004) 300–305.
[19] N. Cannelli, D. Cassandrini, E. Bertini, P. Striano, L. Fusco, R. Gaggero, N. Specchio,
R. Biancheri, F. Vigevano, C. Bruno, A. Simonati, F. Zara, F.M. Santorelli, Novel mu-
tations in CLN8 in Italian variant late infantile neuronal ceroid lipofuscinosis: an-
other genetic hit in the Mediterranean, Neurogenetics 7 (2006) 111–117.
[20] C. Vantaggiato, F. Redaelli, S. Falcone, C. Perrotta, A. Tonelli, S. Bondioni,M.Morbin, D.
Riva, V. Saletti, M.C. Bonaglia, R. Giorda, N. Bresolin, E. Clementi, M.T. Bassi, A novel
540 R. Passantino et al. / Biochimica et Biophysica Acta 1833 (2013) 529–540CLN8mutation in late-infantile-onset neuronal ceroid lipofuscinosis (LINCL) reveals
aspects of CLN8 neurobiological function, Hum. Mutat. 30 (2009) 1104–1116.
[21] A. Messer, J. Plummer, M.C. MacMillen, W.N. Frankel, Genetics of primary and
timing effects in the mnd mouse, Am. J. Med. Genet. 57 (1995) 361–364.
[22] L. Lonka, A. Kyttälä, S. Ranta, A. Jalanko, A.E. Lehesjoki, The neuronal ceroid
lipofuscinosis CLN8 membrane protein is a resident of the endoplasmic reticu-
lum, Hum. Mol. Genet. 9 (2000) 1691–1697.
[23] J.E. Vance, S.J. Stone, J.R. Faust, Abnormalities in mitochondria-associated mem-
brane and phospholipid biosynthetic enzymes in the mnd/mnd mouse model of
neuronal ceroid lipofuscinosis, Biochim. Biophys. Acta 1344 (1997) 286–299.
[24] E. Rusyn, T. Mousallem, D. Persaud-Sawin, S. Miller, R.M. Boustany, CLN3p Im-
pacts Galactosylceramide Transport, Raft Morphology, and Lipid Content, Pediatr.
Res. 63 (2008) 625–631.
[25] M. Kuronen, M. Hermansson, O. Manninen, I. Zech, M. Talvitie, T. Laitinen, O.
Gröhn, P. Somerharju, M. Eckhardt, J.D. Cooper, A.E. Lehesjoki, U. Lahtinen, O.
Kopra, Galactolipid deﬁciency in the early pathogenesis of neuronal ceroid
lipofuscinosis model Cln8(mnd): implications to delayed myelination and oligo-
dendrocyte maturation, Neuropathol. Appl. Neurobiol. 38 (2012) 471–486.
[26] M. Bertamini, B. Marzani, R. Guarneri, P. Guarneri, P. Bigini, T. Mennini, D. Curti,
Mitochondrial oxidative metabolism in motor neuron degeneration (mnd)
mouse central nervous system, Eur. J. Neurosci. 16 (2002) 2291–2296.
[27] R. Guarneri, D. Russo, C. Cascio, S. D'Agostino, G. Galizzi, P. Bigini, T. Mennini, P.
Guarneri, Retinal oxidation, apoptosis and age- and sex-differences in themndmutant
mouse, a model of neuronal ceroid lipofuscinosis, Brain Res. 1014 (2004) 209–220.
[28] J. Kolikova, R. Afzalov, A. Surin, A.E. Lehesjoki, L. Khiroug, Deﬁcient mitochondrial
Ca(2+) buffering in the Cln8(mnd) mouse model of neuronal ceroid lipofuscinosis,
Cell Calcium 50 (2011) 491–501.
[29] G. Galizzi, D. Russo, I. Deidda, C. Cascio, R. Passantino, R. Guarneri, P. Bigini, T. Mennini,
G. Drago, P. Guarneri, Different early ER-stress responses in the CLN8(mnd) mouse
model of neuronal ceroid lipofuscinosis, Neurosci. Lett. 488 (2011) 258–262.
[30] M. Hermansson, R. Käkelä, M. Berghäll, A.E. Lehesjoki, P. Somerharju, U. Lahtinen,
Mass spectrometric analysis reveals changes in phospholipid, neutral
sphingolipid and sulfatide molecular species in progressive epilepsy with mental
retardation, EPMR, brain: a case study, J. Neurochem. 95 (2005) 609–617.
[31] H. Wei, S.J. Kim, Z. Zhang, P.C. Tsai, K.E. Wisniewski, A.B. Mukherjee, ER and oxi-
dative stresses are common mediators of apoptosis in both neurodegenerative
and non-neurodegenerative lysosomal storage disorders and are alleviated by
chemical chaperones, Hum. Mol. Genet. 17 (2008) 469–477.
[32] E. Winter, C.P. Ponting, TRAM, LAG1 and CLN8: members of a novel family of
lipid-sensing domains? Trends Biochem. Sci. 27 (2002) 381–383.
[33] L. Lonka, T. Salonen, E. Siintola, O. Kopra, A.E. Lehesjoki, A. Jalanko, Localization of
wild-type and mutant neuronal ceroid lipofuscinosis CLN8 proteins in non-
neuronal and neuronal cells, J. Neurosci. Res. 76 (2004) 862–871.
[34] D.A. Persaud-Sawin, T. Mousallem, C. Wang, A. Zucker, E. Kominami, R.M.
Boustany, Neuronal ceroid lipofuscinosis: a common pathway? Pediatr. Res. 61
(2007) 146–152.
[35] I. Guillas, J.C. Jiang, C. Vionnet, C. Roubaty, D. Uldry, R. Chuard, J.Wang, S.M. Jazwinski, A.
Conzelmann, Human homologues of LAG1 reconstitute Acyl-CoA-dependent ceramide
synthesis in yeast, J. Biol. Chem. 278 (2003) 37083–37091.
[36] A. Lyly, C. von Schantz, C. Heine, M.L. Schmiedt, T. Sipilä, A. Jalanko, A. Kyttälä,
Novel interactions of CLN5 support molecular networking between neuronal
ceroid lipofuscinosis proteins, BMC Cell Biol. 10 (2009) 83.
[37] C. Heine, A. Quitsch, S. Storch, Y. Martin, L. Lonka, A.E. Lehesjoki, S.E. Mole, T. Braulke,
Topology and endoplasmic reticulum retention signals of the lysosomal storage
disease-related membrane protein CLN6, Mol. Membr. Biol. 24 (2007) 74–87.
[38] I. Stagljar, C. Korostensky, N. Johnsson, S. te Heesen, A genetic system based on
split-ubiquitin for the analysis of interactions between membrane proteins in
vivo, Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 5187–5192.
[39] S. Lev, D. Ben Halevy, D. Peretti, N. Dahan, The VAP protein family: from cellular
functions to motor neuron disease, Trends Cell Biol. 18 (2008) 282–290.
[40] Y. Sagiv, A. Legesse-Miller, A. Porat, Z. Elazar, GATE-16, a membrane transport
modulator, interacts with NSF and the Golgi v-SNARE GOS-28, EMBO J. 19
(2000) 1494–1504.
[41] Y. Kabeya, N. Mizushima, A. Yamamoto, S. Oshitani-Okamoto, Y. Ohsumi, T.
Yoshimori, LC3, GABARAP and GATE16 localize to autophagosomal membrane
depending on form-II formation, J. Cell Sci. 117 (2004) 2805–2812.
[42] H. Weidberg, E. Shvets, T. Shpilka, F. Shimron, V. Shinder, Z. Elazar, LC3 and
GATE-16/GABARAP subfamilies are both essential yet act differently in
autophagosome biogenesis, EMBO J. 29 (2010) 1792–1802.
[43] L. Lonka, A. Aalto, O. Kopra, M. Kuronen, Z. Kokaia, M. Saarma, A.E. Lehesjoki, The
neuronal ceroid lipofuscinosis Cln8 gene expression is developmentally regulated
in mouse brain and up-regulated in the hippocampal kindling model of epilepsy,
BMC Neurosci. 6 (2005) 27.
[44] E. Teuling, S. Ahmed, E. Haasdijk, J. Demmers, M.O. Steinmetz, A. Akhmanova, D.
Jaarsma, C.C. Hoogenraad, Motor neuron disease-associated mutant vesicle-associatedmembrane protein-associated protein (VAP) B recruits wild-type VAPs into endoplas-
mic reticulum-derived tubular aggregates, J. Neurosci. 27 (2007) 9801–9815.
[45] C. Ottolenghi, I. Daizadeh, A. Ju, S. Kossida, G. Renault, M. Jacquet, A. Fellous, W.
Gilbert, R. Veitia, The genomic structure of c14orf1 is conserved across eukarya,
Mamm. Genome 11 (2000) 786–788.
[46] C. Mo, M. Bard, Erg28p is a key protein in the yeast sterol biosynthetic enzyme
complex, J. Lipid Res. 46 (2005) 1991–1998.
[47] S.E. Kaiser, J.H. Brickner, A.R. Reilein, T.D. Fenn, P. Walter, A.T. Brunger, Structural
basis of FFAT motif-mediated ER targeting, Structure 13 (2005) 1035–1045.
[48] M. Kawano, K. Kumagai, M. Nishijima, K. Hanada, Efﬁcient trafﬁcking of ceramide
from the endoplasmic reticulum to the Golgi apparatus requires a
VAMP-associated protein-interacting FFAT motif of CERT, J. Biol. Chem. 281
(2006) 30279–30288.
[49] D. Peretti, N. Dahan, E. Shimoni, K. Hirschberg, S. Lev, Coordinated lipid transfer be-
tween the endoplasmic reticulum and the Golgi complex requires the VAP proteins
and is essential for Golgi-mediated transport, Mol. Biol. Cell 19 (2008) 3871–3884.
[50] P.A. Skehel, R. Fabian-Fine, E.R. Kandel, Mouse VAP33 is associated with the endo-
plasmic reticulum and microtubules, Proc. Natl. Acad. Sci. U. S. A. 97 (2000)
1101–1106.
[51] M.L. Weir, H. Xie, A. Klip, W.S. Trimble, VAP-A binds promiscuously to both v- and
tSNAREs, Biochem. Biophys. Res. Commun. 286 (2001) 616–621.
[52] R. Amarilio, S. Ramachandran, H. Sabanay, S. Lev, Differential regulation of endo-
plasmic reticulum structure through VAP-Nir protein interaction, J. Biol. Chem.
280 (2005) 5934–5944.
[53] N. Rocha, C. Kuijl, R. van der Kant, L. Janssen, D. Houben, H. Janssen, W. Zwart, J.
Neefjes, Cholesterol sensor ORP1L contacts the ER protein VAP to control
Rab7-RILP-p150 glued and late endosome positioning, J. Cell Biol. 185 (2009)
1209–1225.
[54] J.S. Bonifacino, B.S. Glick, The mechanisms of vesicle budding and fusion, Cell 116
(2004) 153–166.
[55] R. Prekeris, B. Yang, V. Oorschot, J. Klumperman, R.H. Scheller, Differential roles of
syntaxin 7 and syntaxin 8 in endosomal trafﬁcking, Mol. Biol. Cell 10 (1999)
3891–3908.
[56] J.T. Kittler, P. Rostaing, G. Schiavo, J.M. Fritschy, R. Olsen, A. Triller, S.J. Moss, The
subcellular distribution of GABARAP and its ability to interact with NSF suggest
a role for this protein in the intracellular transport of GABAA receptors, Mol.
Cell. Neurosci. 18 (2001) 13–25.
[57] J.D. Cooper, C. Russell, H.M. Mitchison, Progress towards understanding disease
mechanisms in small vertebrate models of neuronal ceroid lipofuscinosis,
Biochim. Biophys. Acta 1762 (2006) 873–889.
[58] K. Luiro, O. Kopra, M. Lehtovirta, A. Jalanko, CLN3 protein is targeted to neuronal
synapses but excluded from synaptic vesicles: new clues to Batten disease, Hum.
Mol. Genet. 10 (2001) 2123–2131.
[59] L. Ahtiainen, O.P. Van Diggelen, A. Jalanko, O. Kopra, Palmitoyl protein thioesterase 1
is targeted to the axons in neurons, J. Comp. Neurol. 455 (2003) 368–377.
[60] V. Kirkin, D.G. McEwan, I. Novak, I. Dikic, A role for ubiquitin in selective
autophagy, Mol. Cell 34 (2009) 259–269.
[61] I. Novak, V. Kirkin, D.G. McEwan, J. Zhang, P. Wild, A. Rozenknop, V. Rogov, F.
Löhr, D. Popovic, A. Occhipinti, A.S. Reichert, J. Terzic, V. Dötsch, P.A. Ney, I.
Dikic, Nix is a selective autophagy receptor for mitochondrial clearance, EMBO
Rep. 11 (2010) 45–51.
[62] J. Zhang, P.A. Ney, Role of BNIP3 and NIX in cell death, autophagy, and mitophagy,
Cell Death Differ. 16 (2009) 939–946.
[63] C. Settembre, A. Fraldi, L. Jahreiss, C. Spampanato, C. Venturi, D. Medina, R. de
Pablo, C. Tacchetti, D.C. Rubinsztein, A. Ballabio, A block of autophagy in lysosom-
al storage disorders, Hum. Mol. Genet. 17 (2008) 119–129.
[64] M. Koike, M. Shibata, S. Waguri, K. Yoshimura, I. Tanida, E. Kominami, T. Gotow, C.
Peters, K. von Figura, N. Mizushima, P. Saftig, Y. Uchiyama, Participation of
autophagy in storage of lysosomes in neurons from mouse models of neuronal
ceroid-lipofuscinoses (Batten disease), Am. J. Pathol. 167 (2005) 1713–1728.
[65] N. Cannelli, B. Garavaglia, A. Simonati, C. Aiello, C. Barzaghi, F. Pezzini, M.R. Cilio,
R. Biancheri, M. Morbin, B. Dalla Bernardina, T. Granata, A. Tessa, F. Invernizzi, A.
Pessagno, R. Boldrini, F. Zibordi, L. Grazian, D. Claps, R. Carrozzo, S.E. Mole, N.
Nardocci, F.M. Santorelli, Variant late infantile ceroid lipofuscinoses associated
with novel mutations in CLN6, Biochem. Biophys. Res. Commun. 379 (2009)
892–897.
[66] M. Thelen, M. Damme, M. Schweizer, C. Hagel, A.M. Wong, J.D. Cooper, T. Braulke,
G. Galliciotti, Disruption of the autophagy-lysosome pathway is involved in neu-
ropathology of the nclf mouse model of neuronal ceroid lipofuscinosis, PLoS One
7 (2012) e35493.
[67] C.K. Zhang, P.B. Stein, J. Liu, Z. Wang, R. Yang, J.H. Cho, P.K. Gregersen, J.M. Aerts,
H. Zhao, G.M. Pastores, P.K. Mistry, Genome-wide association study of N370S ho-
mozygous Gaucher disease reveals the candidacy of CLN8 gene as a genetic mod-
iﬁer contributing to extreme phenotypic variation, Am. J. Hematol. 87 (2012)
377–383.
